Rino Rappuoli | |
|---|---|
.jpg) Rappuoli in 2016 | |
| Born | (1952-08-04)4 August 1952 (age 72)[2] Radicofani, Italy |
| Scientific career | |
| Fields | |
| Website | www |
Rino RappuoliForMemRS (born 4 August 1952) is an Italianimmunologist. He is the head of vaccineresearch and development (R&D) atGlaxoSmithKline (GSK) Vaccines.[1] Previously, he has served as visiting scientist atRockefeller University andHarvard Medical School and held roles at Sclavo, Vaccine Research and CSO, Chiron Corporation, andNovartis Vaccines.[3][4][5]
Rappuoli earned his doctoral and bachelor's degrees in biological sciences at theUniversity of Siena.[6]
He is known globally for his work invaccines andimmunology. He co-founded the field of cellular microbiology, a discipline combiningcell biology andmicrobiology, and pioneered the genomic approach to vaccine development known asreverse vaccinology, a subsection ofreverse pharmacology.[6]
Rappuoli ledChiron Corporation's development of adjuvantedinfluenza vaccines, MENJUGATE(R) conjugate vaccine againstmeningococcal-C disease and the first recombinant bacterial vaccine againstpertussis.[citation needed] He is actively involved in the research and development of further vaccines against meningococcal disease andavian and pandemic influenza.[1]
Rappuoli joined Chiron as head of European vaccines research in 1992 with the acquisition of Italian vaccines company Sclavo SpA, where he served as head of research and development. Rappuoli, was previously the global head of vaccines research for Novartis Vaccines & Diagnostics (Siena, Italy)[6] Since 2015, Dr. Rappuoli serves as the chief scientist and head of external R&D at the vaccines division of GlaxoSmithKline and is based in Siena, Italy.[7]
Major achievements include development ofCRM197[8] used inHaemophilus influenzae,Neisseria meningitidis,[9] andpneumococcusvaccines; an acellularpertussis vaccine containing a genetically detoxified pertussis toxin; the first conjugate vaccines againstmeningococcus;MF59adjuvant for influenza;[10][11] the meningococcus Bgenome-derived vaccine.[3][12]
During his career, he has introduced several novel scientific concepts: genetic detoxification in 1987;[13]cellular microbiology in 1996;[14] reverse vaccinology in 2000;[15]pan-genome in 2005.[3][16]
Rappuoli is the recipient of several prestigious awards, including thePaul Ehrlich and Ludwig Darmstaedter Prize in 1991. He is a member of numerous international associations, including theEuropean Molecular Biology Organization and theAmerican Society for Microbiology. He also serves as a member of the research directors group of theEuropean Commission and in 2005[6] was elected toNational Academy of Sciences of theUnited States. He was also awarded the Italian President Gold Medal in 2005 and theAlbert Sabin Gold Medal in 2009.[3] In 2013 he was nominated third most influential person worldwide in the field of vaccines by Terrapin. In 2015 he was awarded Fellowship ofImperial College London Faculty of Medicine and theMaurice Hilleman Award.[3]
In 2016 he was elected aForeign Member of the Royal Society.[3]
In 2017 he received theEuropean Inventor Award 2017 in the category of "Lifetime achievement" by theEuropean Patent Office.[17] In 2019 he was awarded theRobert Koch Prize.[18]
All text published under the heading 'Biography' on Fellow profile pages is available underCreative Commons Attribution 4.0 International License." --"Royal Society Terms, conditions and policies". Archived from the original on September 25, 2015. Retrieved2016-03-09.
{{cite web}}: CS1 maint: bot: original URL status unknown (link)
| International | |
|---|---|
| National | |
| Academics | |
| People | |
| Other | |